Clinical Trial Update: Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating SBK2-ICG for fluorescence-guided imaging of malignant brain tumors, including glioma. The trial is currently NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioma

Drugs mentioned

• SBK2-ICG

Snippet

Sponsor: Tiffany Hodges | Conditions: Malignant Brain Tumors, Glioma | Phase 1 | Status: NOT_YET_RECRUITING